Perycit (Pentaerythriol Tetranicotinate), a slow releasing
drug, is one of the drugs used for treating
hyperlipemia. Patients with
erectile dysfunction (
impotence) associated with
hyperlipemia increasingly seek help at urological services. This study investigates the clinical effect, both objective and subjective of
Perycit on anti-
hyperlipemia as well as on
impotence. Twenty patients with a more than one year history of
impotence with
hyperlipemia were enrolled in this randomized, single-blind study. Decrease of total
cholesterol, and
triglyceride, as well as the increase of
high density lipoprotein cholesterol in the study group (
Perycit, 500 mg, tid, for 3 months) were significantly different from the pre-treatment period and in the control group (
Trental, 100 mg, tid, for 3 months) (p < 0.05 or p < 0.01). Moreover, improvement in sexual function was shown to be better in the study group than in either the pretreatment period and control groups, objectively and subjectively (p < 0.05 or p < 0.01). Tolerable facial flush was found in 3 of these 20 patients, but no major side effects were encountered. In conclusion, this study indicates
Perycit is effective for anti-
hyperlipemia as well as for aiding improvement of sexual dysfunction. Since it is a slow-releasing preparation, the side effect is minimal. It is recommended for patients with
hyperlipemia alone, or those who suffer from combined
erectile dysfunction.